Perrigo-Agis deal
This article was originally published in The Tan Sheet
Executive Summary
Perrigo has completed its acquisition of Israeli generic manufacturer Agis Industries, the firm announces March 17. Perrigo shareholders approved the issuance of common stock related to the deal on March 15; Agis shareholders approved the transaction on the same day. The deal was announced in November (1"The Tan Sheet" Nov. 22, 2004, p. 6)..
You may also be interested in...
Perrigo naproxen approval
Private labeler receives FDA approval to manufacture and market Rx naproxen tablets in 250 mg, 375 mg and 500 mg doses, Perrigo announces April 28. The product, equivalent to Roche's Naprosyn, is "indicated for the treatment of arthritis, tendonitis, bursitis and for the relief of mild to moderate pain," according to Perrigo. The firm completed its acquisition of generic drug manufacturer Agis last month (1"The Tan Sheet" March 21, 2005, In Brief)...
Perrigo Moves In On Major Generic Firms With Agis Acquisition
Perrigo's acquisition of Israeli generic drug firm Agis Pharmaceuticals will put the combined entity's annualized sales over the $1 bil. mark and in the same league with major Rx generic drug players
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”